Brief: Karyopharm Therapeutics Inc - On February 27, 2026,Co Enters Second Amendment To Credit Agreement - SEC Filing
03/03/2026 11:31
March 3 (Reuters) - SEC Filing: KARYOPHARM THERAPEUTICS INC - ON FEBRUARY 27, 2026,CO ENTERS SECOND AMENDMENT TO CREDIT AGREEMENT - SEC FILING KARYOPHARM THERAPEUTICS INC - AMENDMENT ALLOWS CO DEFERRAL OF PAYMENTS UNTIL SEPTEMBER 2026 - SEC FILING KARYOPHARM THERAPEUTICS: AMENDMENT TO ELIMINATE REQUIREMENT THAT 50% OF FINANCING PROCEEDS BE APPLIED TOWARD INCREASING MINIMUM LIQUIDITY COVENANT Source text: [ID:n0001503802-26-000006] Further company coverage: KPTI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview